Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: SPSEIFERT who wrote (214)	4/26/2004 2:15:24 PM
From: tuck	Read Replies (1) \| Respond to of 447

>>What about LGND<< LGND's oncology products have completely different targets and mechanisms of action. Should be no effect, or even negative if the OSI drug works as well as the market today would have you believe. I don't think so, the trial was against supportive care, not the gold standard as were the other EGFr drugs. Tarceva, Avastin, Erbitux, ABX-EGF, all variations on a theme, and all very expensive. 5 million+ shares short seems to be creating a little squeeze: nasdaqtrader.com But I don't think OSIP will hold $90 for long. Only 3% of float short. This is overdone mo-mo hype. Other sympathy plays should also come back down, IMO. I expect them (non-EGFr players) to give back most of the gains, while OSI should hold on to a good chunk of them. Cheers, Tuck